| Title |
The Novel Deacetylase Inhibitor AR-42 Demonstrates Pre-Clinical Activity in B-Cell Malignancies In Vitro and In Vivo
|
|---|---|
| Published in |
PLOS ONE, June 2010
|
| DOI | 10.1371/journal.pone.0010941 |
| Pubmed ID | |
| Authors |
David M. Lucas, Lapo Alinari, Derek A. West, Melanie E. Davis, Ryan B. Edwards, Amy J. Johnson, Kristie A. Blum, Craig C. Hofmeister, Michael A. Freitas, Mark R. Parthun, Dasheng Wang, Amy Lehman, Xiaoli Zhang, David Jarjoura, Samuel K. Kulp, Carlo M. Croce, Michael R. Grever, Ching-Shih Chen, Robert A. Baiocchi, John C. Byrd |
| Abstract |
While deacetylase (DAC) inhibitors show promise for the treatment of B-cell malignancies, those introduced to date are weak inhibitors of class I and II DACs or potent inhibitors of class I DAC only, and have shown suboptimal activity or unacceptable toxicities. We therefore investigated the novel DAC inhibitor AR-42 to determine its efficacy in B-cell malignancies. |
Mendeley readers
The data shown below were compiled from readership statistics for 39 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 3% |
| Unknown | 38 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 11 | 28% |
| Student > Ph. D. Student | 7 | 18% |
| Student > Bachelor | 5 | 13% |
| Professor > Associate Professor | 3 | 8% |
| Student > Doctoral Student | 2 | 5% |
| Other | 5 | 13% |
| Unknown | 6 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 11 | 28% |
| Agricultural and Biological Sciences | 11 | 28% |
| Medicine and Dentistry | 4 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 5% |
| Chemistry | 2 | 5% |
| Other | 1 | 3% |
| Unknown | 8 | 21% |